Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.54 |
| ▸ | BRAF | P15056 | 12/20 | 0.47 |
| ▸ | RAF1 | P04049 | 11/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10118868 | 0.87 | PIK3CA (0.46) | PIK3CABRAFRAF1MAPK13MAPK14 | |
| SCHEMBL10118974 | 0.85 | ALDH1A1 (0.48) | BRAFPRMT5 | |
| SCHEMBL12516627 | 0.81 | CTSB (0.61) | PRMT5 | |
| SCHEMBL12518285 | 0.81 | PIK3CA (0.50) | PIK3CABRAFRAF1MAPK13MAPK14 | |
| SCHEMBL13702161 | 0.81 | PIK3CA (0.65) | PIK3CABRAFRAF1MAPK13MAPK14 | |
| SCHEMBL13701811 | 0.76 | PIK3CA (0.65) | PIK3CABRAFRAF1MAPK13MAPK14 | |
| SCHEMBL10119267 | 0.75 | FDPS (0.42) | PIK3CABRAF | |
| SCHEMBL10118924 | 0.75 | CA2 (0.49) | — | |
| SCHEMBL13702422 | 0.75 | PIK3CA (0.70) | PIK3CABRAFRAF1MAPK13MAPK14 | |
| SCHEMBL10118871 | 0.73 | ALDH1A1 (0.43) | BRAFPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2526116-B1 | PYRUVAMIDE COMPOUNDS AS INHIBITORS OF DUST MITE GROUP 1 PEPTIDASE ALLERGEN | ST GEORGES HOSP MEDICAL SCHOOL (GB) | 2015-05-13 | — | — | EP | disclosed |
| US-8637453-B2 | Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2014-01-28 | — | — | US | disclosed |
| US-8541363-B2 | Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use | St George's Hosptial Medical School (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20130217617-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | THE UNIVERSITY OF MANCHESTER (GB) | 2013-08-22 | — | — | US | disclosed |
| US-20120322722-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | THE UNIVERSITY OF MANCHESTER (GB) | 2012-12-20 | — | — | US | disclosed |
| WO-2012004554-A1 | ALDEHYDE COMPOUNDS AS INHIBITORS OF DUST MITE GROUP 1 PEPTIDASE ALLERGEN AND THEIR USE | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2011089396-A2 | PYRUVAMIDE COMPOUNDS AS INHIBITORS OF DUST MITE GROUP 1 PEPTIDASE ALLERGEN AND THEIR USE. | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217617-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | PREP, DPEP1, DPP8 | PIK3CA 571/4885BRAF 3376/4885RAF1 2136/4885 |
| US-20120322722-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | PREP, DPEP1, PEPD | PIK3CA 651/4885BRAF 3378/4885RAF1 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.